Genetic profile and molecular bases of pancreatic carcinogenesis;Perfil genético y bases moleculares de la carcinogénesis pancreática

Gastroenterologia y Hepatologia

Volumn 30, Issue 10, 2007, Pages 592-596

  Sánchez Fayos Calabuig, Paloma ^a,b   Relloso, María Jesús Martín ^a   Cubero, Juan Carlos Porres ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16; PROTEIN P53; SMAD4 PROTEIN;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; HISTOPATHOLOGY; HUMAN; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA;

EID: 37149014435     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1157/13112587     Document Type: Article

References (51)

1. Jemal A, Thomas A, Murray T. Cancer statistics 2002. CA Cancer J Clin. 2002;52:23-47.
2. Warshaw AL, Fernández del Castillo C. Medical progress: pancreatic carcinoma. N Engl J Med. 1992;326:455-65.
3. Fernández del Castillo C, Jiménez RE. Pancreatic cancer, cystic pancreatic neoplasms an other nonendocrine pancreatic tumors. En: Sleisenger and Fordtran's gastrointestinal and liver disease. 7th ed. Philadelphia: Saunders; 2002. p. 970-87.
4. Nowell PC. The clonal evolution of tumor cell population. Science. 1976;194:23-5.
5. Weinberg RA. Oncogenes, antioncogenes and the molecular bases of multistep carcinogenesis. Cancer Res. 1998;49:3713-21.
6. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet. 1993;9:138-52.
7. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-67.
8. Hahn SA, Kem SE. Molecular genetics of exocrine pancreatic neoplasms. Surg Clin North Am. 1995;75:857-69.
9. Hruban RH, Iacrobuzio-Donahue C, Wilentz RE. Molecular pathology of pancreatic cancer. Cancer J. 2001;7:251-62.
10. Hilgers W, Rosty C, Hahn SA. Molecular pathogenesis of pancreatic cancer Hematol Oncol Clin North Am. 2002;16:17-35.
11. Lowenfelds AB, Maisonneuve P, Cavallini G: Pancreatitis and the risk of pancreatic cancer. N Engl J Med. 1993;328:1433-7.
12. Cubilla AL, Fitzgerald PJ. Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res. 1976;36:2690-8.
13. Kozuka S, Sassa R, Takai T, Masamoto K, Nagasawa S, Saga S, et al. Relation of pancreatic duct hiperplasia to carcinoma. Cancer. 1979;43:1418-28.
14. Hruban RH, Adsay NV, Albores-Saavedra J, Compton C, Garrett ES, Goodman SN, et al. Pancreatic intraepitelial neoplasia: a new nomenclature and classification systems for pancreatic duct lesions. Am J Surg Pathol. 2001;25:579-86.
15. Bardeesy N, De Pinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002;2:897-909.
16. Barbacid M. ras genes. Annu Rev Biochem. 1987;56:770-827.
17. Almoguera C, Shibata D, Forrester K, Martin J, Amheim N, Perucho M, et al. Most human carcinomas of the exocrine pancreas contain mutant K-ras genes. Cell. 1988;53:549-54.
18. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682-9.
19. Hruban RH, Van Mansfield AD, Offer Haus GJ, Van Weering DH, Allison DC, Goodman SN, et al. K-ras oncogenes activation in adenocarcinoma of human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polimerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol. 1993;143:545-54.
20. Jiménez RE, Warshaw AL, Z'Graggen K. Sequential accumulation of K-ras mutations and p53 overexpression of pancreatic mucinous cystic neoplasms to malignancy. Ann Surg. 1999;230:501-11.
21. Pellegata NS, Sessa F, Renault B, Bonato M, Leone BE, Soleia E, et al. K-ras and p53 gene mutations in pancreatic cancer. Ductal and nonductal tumors progress through different genetic lessions. Cancer Res. 1994;54:1556-60.
22. Weinberg RA. Tumor suppresor genes Science. 1991;254:1138-45.
23. Marshall CJ. Tumor suppressor genes. Cell. 1991;64:313-26.
24. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, et al. Tumor suppressive pathways in pancreatic carcinoma. Cancer Res. 1997;57:1731-4.
25. Nobori T, Miura K, Wu DJ. Deletion of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1994;368:753-6.
26. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al. A cell cycle regulator potencially involved in genesis of many tumor types. Science. 1994;264:436-40.
27. Caldas C, Hahn SA, Da Costa LT, Redston MS, Schutte M, Seymour AB, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet. 1994;8:27-32.
28. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 1997;57:3126-30.
29. Kern SE, Kinzler KW, Baker SJ, Nigro JM, Rotter V, Levine AJ, et al. Mutant p53 protein bind DNA abnormally in vitro. Oncogene. 1991;6:131-6.
30. Levine AJ, Momand J, Finaly CA. The p53 tumor suppressor gene Nature. 1991;351:453-6.
31. Rotter V, Prokozimer M. p53 and human malignancies. Adv Cancer Res. 1991;57:257-72.
32. Vogelstein B, Kinzier KW. p53 funetion and dysfunction. Cell. 1992;70:523-6.
33. Signal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 2000;60:6788-93.
34. Barton CM, Staddon SL, Hughes CM. Abnormalities of p53 tumor suppressor gene in human pancreatic cancer. Br J Cancer. 1991;64:1076-85.
35. Hahn SA, Schutte M, Shamsul K, Hoque ATM, Moskaluk CA, Da Costa LT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q2.1. Science. 1996;271:350-3.
36. Chiao PJ, Hunt KK, Grau AM. Tumor suppressor gene SMAD4/DPC4, its downstream target genes and regulation of cell cycle. Ann NY Acad Sci. 1999;880:31-7.
37. Chung DC, Rustgi AK. DNA mismatch repair and cancer. Gastroenterology. 1995;109:1685-99.
38. Ghimenti C, Tannergard P, Wahlberg S. Microsatellite instability and mismatch repair gene inactivation in sporadic pancreatic and colon tumors. Br J Cancer. 1999;80:11-21.
39. Yamamoto H, Itoh F, Nakamura H, Fukushima H, Sasaki S, Perucho M, et al. Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. Cancer Res. 2001;61:3139-44.
40. Goggins M, Offerhaus GJ, Hilgers W, Griffin CA, Shekher M, Tang D, et al. Pancreatic adenocarcinoma with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Am J Pathol. 1998;152:1501-7.
41. Friess H, Berberat P, Schilling M. Pancreatic cancer: the potencial clinical relevance of alterations in growth factors and others receptors. J Mol Med. 1996;74:35-44.
42. Hahn WC. Role of telomers ans telomerase in the pathogenesis of human cancer. J Clin Oncol. 2003;21:2034-43.
43. Sánchez-Fayos P, Juzgado D, Bosch O, González-Guirado A, Porres JC. Carcinoma colorrectal: circunstancias inductores y vías de realización. Rev Clin Esp. 2000;200:605-15.
44. Lowenfelds AB, Maisonneuve P. Epidemiologic and etiologic factors os pancreatic cancer. Hematol. Oncol Clin North Am. 2002;16:1-16.
45. Kalthoff H, Schmiegel W, Reeder C, Kasche D, Schmidt A, Laver G, et al. p53 and K-ras alterations in pancreatic epithelial cell lesions. Oncogene. 1993;8:289-98.
46. Di Giuseppe JA, Hruban RH, Offerhaus GJ, Clement MJ, Van den Berg FM, Cameron JL, et al. Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. Am J Pathol. 1994; 144:889-95.
47. Tada M, Ohashi M, Shiratori Y, Okudaira T, Komatsu Y, Kawabe T, et al. Analysis os K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology. 1996;110:227-31.
48. Moskaluk CA, Hruban RH, Kern SE. p16 and K-ras mutation in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res. 1997;57:2140-3.
49. Luttges J, Reineke-Luthge A, Mollmann B, Menke MA, Clemens A, Klimpfinger M, et al. Duct changes and K-ras mutations in the disease-free pancreas. Wirchows Arch. 1999;435:461-8.
50. Rivera JA, Rall CJN, Graeme-Cook F. Analysis of K-ras oncogene mutations in chronic pancreatitis with ductal hyperplasia. Surgery. 1997;121:42-9.
51. Wilentz RE, Iacobuzio-Donahue CA, Argani P, McKarthy DM, Parsons JL, Yeo CJ, et al. Loss of expression of DPC4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res. 2000;60:2002-6.